Form 10-Q ALNYLAM PHARMACEUTICALS, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Alnylam Pharmaceuticals (ALNY) PT Lowered to $116 at BMO Capital
November 8, 2018 8:56 AM ESTBMO Capital analyst Do Kim lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $116.00 (from $124.00) while maintaining a Outperform rating.
Kim commented, "We lower our estimates and target price to $116 from $124, following 3Q18 earnings that saw modest initial Onpattro sales... More
